Changes to patent laws would speed access to lower-cost drugs
Regarding the article “Brandeddrug price hikes dwarf higher utilization of lower-cost generics” (ModernHealthcare.com, Nov. 16; also on p. 16 of this issue), higher utilization of a lower-cost product? Sounds to me like the generic-drug market is doing exactly what we want it to do, and name-brand pharmaceuticals are behaving exactly as you would expect any industry would when granted a government-sanctioned monopoly.
I believe if we continue opening the door for generics, the market will eventually put downward pressure on the price of name-brand medications. But if we want to see that happen faster, we need to do something about the patent laws. Joshua Naatjes Madison, Wis.